The final results of a pioneering, randomised controlled study in patients with inflammatory bowel disease (IBD) have helped to better define the role of drug level monitoring during infliximab treatment.1 Researchers in Belgium have confirmed that, while there are substantial advantages to using infliximab drug levels to guide dosing during optimisation of infliximab therapy, continuous drug level monitoring is not needed to maintain this effect...
More...
More...